Paper Details

  1. Home
  2. Paper Details

Two-Drug Cocktail Active against RCC.

Author:

NewsMedia reports that provide information on the latest events and information. Newspapers, television, and the Internet are the main media.

Overview

Avelumab and axitinib combined showed a 64% increase in progression-free survival compared to sunitinib in advanced renal cell carcinoma patients. Response rates were 51% vs. 26%, with similar side effects in both groups.
Paper Details　
Original Abstract of the Article :
The combination of avelumab and axitinib increases progression-free survival by 64% over sunitinib in patients with advanced renal cell carcinoma. The drug duo triggered responses in 51% of patients, whereas sunitinib induced responses in 26%. Side effects of grade 3 or 4 were similar in both groups...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/2159-8290.CD-NB2018-152

データ提供：米国国立医学図書館（NLM）

A New Dawn in the Desert of Renal Cell Carcinoma

Renal cell carcinoma (RCC), a complex and often challenging disease, continues to be a significant health concern. This study explores the potential of avelumab and axitinib, a drug combination, in treating advanced RCC. The authors investigated the efficacy of this combination in comparison to sunitinib, a standard-of-care treatment for advanced RCC, in terms of progression-free survival (PFS) and response rates. The study aimed to evaluate the potential of this new drug combination to offer a significant improvement in treatment outcomes for patients with advanced RCC.

A Promising New Horizon

The study's findings suggest that avelumab and axitinib may offer a significant improvement in treatment outcomes for patients with advanced RCC. The combination demonstrated a substantial increase in PFS and higher response rates compared to sunitinib, indicating its potential to become a new standard of care in the treatment of advanced RCC.

A Brighter Future for Patients

This research offers a glimmer of hope for patients with advanced RCC. The development of new and effective treatments like avelumab and axitinib holds the promise of improving treatment outcomes and enhancing the quality of life for individuals facing this challenging disease.

Dr. Camel's Conclusion

This study represents a significant step forward in the treatment of advanced renal cell carcinoma. The remarkable improvement in PFS and response rates observed with the combination of avelumab and axitinib offers a promising new path for patients facing this challenging disease. This discovery could usher in a new era of hope and resilience for those battling RCC.

Date :
  1. Date Completed n.d.
  2. Date Revised 2019-11-20
Further Info :

Pubmed ID

30413405

DOI: Digital Object Identifier

10.1158/2159-8290.CD-NB2018-152

Related Literature

Article Analysis
・Side Effects of axitinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.